Loading...
XKRX006280
Market cap1.34bUSD
Dec 24, Last price  
174,100.00KRW
1D
2.10%
1Q
8.27%
Jan 2017
8.41%
Name

Green Cross Corp

Chart & Performance

D1W1MN
XKRX:006280 chart
P/E
—
P/S
1.22
EPS
—
Div Yield, %
1.25%
Shrs. gr., 5y
—
Rev. gr., 5y
4.03%
Revenues
1.63t
-4.95%
442,299,046,000516,096,685,000643,208,349,000791,015,317,000767,911,770,550811,774,313,000888,168,207,110975,327,105,7301,047,812,247,3301,197,903,918,4001,287,916,286,2201,334,877,810,1101,369,709,726,8001,504,115,278,6501,537,825,750,2501,711,312,739,5301,626,643,815,820
Net income
-26.63b
L
44,357,145,00048,872,734,00080,524,433,000104,688,642,00055,367,168,00053,643,053,42070,066,278,51083,944,674,44094,967,401,93062,969,546,58053,246,604,74034,429,474,380-11,287,400,06081,048,858,100123,211,805,90065,453,133,850-26,631,783,140
CFO
-5.47b
L
35,223,947,000-20,729,139,000112,006,156,00084,471,459,00054,855,488,03050,756,715,57029,689,475,48056,763,005,92045,243,777,660-1,742,284,53057,879,006,00014,410,216,14040,291,382,03035,973,500,910125,978,948,880119,154,310,880-5,472,809,765
Dividend
Dec 27, 20231500 KRW/sh
Earnings
Jan 29, 2025

Profile

Green Cross Corporation, a biopharmaceutical company, develops drugs and vaccines in South Korea. The company provides plasma derivatives, including albumin, immunoglobulin, and antithrombin; and vaccines for hepatitis-B, Hantavirus hemorrhagic fever, influenza, flu, and varicella. It also offers prescription drugs for the bleeding symptom control and hemostasis for persons with hemophilia A; prevention and treatment of bleeding episodes induced by hemophilia A and post-operative treatment; and treatment of neutropenia, hunter syndrome, and liver cancer, as well as treatment of anti-inflammation, pain relief, and osteoarthritis. In addition, the company provides over the counter drugs. It also exports its products to approximately 50 countries. The company has a licensing and collaboration agreement with Tottori University for development of GM1 gangliosidosis chaperone therapy. The company was formerly known as Sudo Microorganism Medical Supplies Company and changed its name to Green Cross Corporation in 1971. Green Cross Corporation was founded in 1967 and is headquartered in Yongin-si, South Korea. Green Cross Corporation is a subsidiary of Green Cross Holdings Corporation.
URL
http://gcbiopharma.com/
IPO date
Aug 01, 1989
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,626,643,816
-4.95%
1,711,312,740
11.28%
1,537,825,750
2.24%
Cost of revenue
1,449,900,646
1,485,926,073
1,332,389,129
Unusual Expense (Income)
NOPBT
176,743,170
225,386,666
205,436,621
NOPBT Margin
10.87%
13.17%
13.36%
Operating Taxes
(7,326,032)
16,313,075
35,609,407
Tax Rate
7.24%
17.33%
NOPAT
184,069,202
209,073,591
169,827,214
Net income
(26,631,783)
-140.69%
65,453,134
-46.88%
123,211,806
52.02%
Dividends
(24,824,693)
(23,985,081)
(18,511,074)
Dividend yield
1.73%
1.62%
0.74%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
532,595,835
198,995,806
235,261,508
Long-term debt
312,297,668
485,877,823
472,167,690
Deferred revenue
15,884,214
22,693,024
24,589,660
Other long-term liabilities
25,010,374
17,558,438
11,733,652
Net debt
588,541,230
363,234,636
410,406,744
Cash flow
Cash from operating activities
(5,472,810)
119,154,311
125,978,949
CAPEX
(125,991,501)
(94,690,240)
(123,538,692)
Cash from investing activities
(150,243,304)
(205,259,307)
(132,077,425)
Cash from financing activities
100,511,823
(2,480,543)
(41,270,329)
FCF
39,216,405
226,773,439
35,036,130
Balance
Cash
55,506,128
112,305,916
202,935,277
Long term investments
200,846,144
209,333,077
94,087,177
Excess cash
175,020,082
236,073,357
220,131,166
Stockholders' equity
1,181,960,389
1,998,044,166
1,856,586,214
Invested Capital
2,129,759,976
1,924,774,520
1,885,200,816
ROIC
9.08%
10.98%
9.76%
ROCE
7.66%
10.42%
9.75%
EV
Common stock shares outstanding
11,413
11,413
11,413
Price
125,500.00
-3.09%
129,500.00
-40.60%
218,000.00
-46.31%
Market cap
1,432,353,839
-3.09%
1,478,006,551
-40.60%
2,488,072,804
-46.31%
EV
2,260,522,085
2,079,760,688
3,123,466,052
EBITDA
252,298,170
290,482,666
261,340,621
EV/EBITDA
8.96
7.16
11.95
Interest
28,483,187
18,392,691
12,501,000
Interest/NOPBT
16.12%
8.16%
6.09%